Scarica l'app Stockscreener
12.37
3.81%
-0.49
Dopo l'orario di chiusura:
12.45
0.08
+0.65%
Precedente Chiudi:
$12.86
Aprire:
$12.88
Volume 24 ore:
837.52K
Relative Volume:
0.77
Capitalizzazione di mercato:
$1.25B
Reddito:
-
Utile/perdita netta:
$-167.48M
Rapporto P/E:
-6.3436
EPS:
-1.95
Flusso di cassa netto:
$-197.47M
1 W Prestazione:
+1.31%
1M Prestazione:
-2.37%
6M Prestazione:
-13.56%
1 anno Prestazione:
-17.81%
Intervallo 1D:
$12.34
$13.01
Intervallo di 1 settimana:
$12.24
$13.53
Portata 52W:
$11.13
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Confronta DAWN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.37 | 1.25B | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
SG Americas Securities LLC Buys New Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of Directors - Yahoo Finance
SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Reviewing Day One Biopharmaceuticals (NASDAQ:DAWN) and Nature’s Sunshine Products (NASDAQ:NATR) - Defense World
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
(DAWN) Trading Report - Stock Traders Daily
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? - Yahoo Finance
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5) - Seeking Alpha
Where are the Opportunities in (DAWN) - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha
(DAWN) On The My Stocks Page - Stock Traders Daily
High Growth Tech Stocks to Watch in December 2024 - Simply Wall St
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat
5 Companies That Celebrated First Approvals in 2024 - BioSpace
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
State Street Corp Sells 3,003 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan
Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Children's Brain Tumor Network Partners with Day One Biopharmaceuticals to Drive New Therapies for Pediatric Brain Tumors - Marketscreener.com
Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com
Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
689,655 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Has $30.31 Million Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Samsara BioCapital LLC Has $2.05 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Fmr LLC Boosts Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Erste Asset Management GmbH Invests $725,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Braidwell LP Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Algert Global LLC Has $996,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Vestal Point Capital LP Boosts Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71 - MarketBeat
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):